New psychoactive substance use as a survival strategy in rural marginalised communities in Hungary

2020 ◽  
Vol 85 ◽  
pp. 102639 ◽  
Author(s):  
Róbert Csák ◽  
Judit Szécsi ◽  
Sziliva Kassai ◽  
Ferenc Márványkövi ◽  
József Rácz
Author(s):  
Jonathan Melamed ◽  
Roy Gerona ◽  
Paul D Blanc ◽  
Paul Takamoto ◽  
Stephanie Conner ◽  
...  

Abstract Gamma-hydroxybutyrate (GHB) is misused as an intoxicant, either alone or concurrently with other substances. Because GHB is illegal, the precursor chemicals 1,4-butanediol and gamma-butyrolactone are also misused for the same effect, either through pre-ingestion alteration or endogenous metabolism to GHB. We describe a case of a 50-year-old man with a history of polysubstance misuse who experienced an overdose of GHB from gamma-butyrolactone ingestion. The patient also co-ingested a common industrial solvent, N-methyl-2-pyrrolidone (NMP). This co-ingested substance raised theoretical concern of metabolism to a GHB congener, underscoring that the emergence of new psychoactive substance use patterns requires ongoing vigilance and toxicologic confirmation.


2020 ◽  
Vol 731 ◽  
pp. 139209 ◽  
Author(s):  
Richard Bade ◽  
Jason M. White ◽  
Lynn Nguyen ◽  
Benjamin J. Tscharke ◽  
Jochen F. Mueller ◽  
...  

2017 ◽  
Vol 43 ◽  
pp. 23-32 ◽  
Author(s):  
Rachel Sutherland ◽  
Raimondo Bruno ◽  
Amy Peacock ◽  
Simon Lenton ◽  
Allison Matthews ◽  
...  

2016 ◽  
Vol 161 ◽  
pp. 110-118 ◽  
Author(s):  
Rachel Sutherland ◽  
Amy Peacock ◽  
Elizabeth Whittaker ◽  
Amanda Roxburgh ◽  
Simon Lenton ◽  
...  

2018 ◽  
Vol 26 (3) ◽  
pp. 179-185 ◽  
Author(s):  
Magdalene HY Tang ◽  
LY Hung ◽  
CK Lai ◽  
CK Ching ◽  
Tony Wing Lai Mak

Background: New psychoactive substances are constantly evolving structural analogues of traditional drugs of abuse that have become a threat to public health worldwide and within our locality. An understanding of the local pattern of new psychoactive substance use will help guide frontline clinical management. Objectives: This study was conducted to review the new psychoactive substances detected in cases referred to the authors’ laboratory (a tertiary clinical toxicology centre), as well as the associated clinical features and toxicological findings. Methods: All cases referred to the laboratory for toxicology analysis between January 2009 and December 2017, and which were analytically confirmed to involve new psychoactive substance use, were retrospectively reviewed. Demographic data, clinical features and toxicology findings were studied. Results: A total of 111 cases involving 104 patients and 22 types of new psychoactive substances were identified, with an increasing trend in the number of cases and subclass of new psychoactive substances detected. Up to half of the cases (n = 64) were related to the use of 2-phenyl-2-(ethylamino)-cyclohexanone (2-oxo-PCE, a ketamine analogue); other new psychoactive substances detected included para-methoxymethamphetamine, 4-fluoroamphetamine, phenazepam, 3-trifluoromethylphenylpiperazine, 5-methoxy-diisopropyltryptamine, 2-diphenylmethylpyrrolidine, methoxyphenidine, the N-methoxybenzyl drugs, cathinones, synthetic cannabinoids and opioids. Among the acute poisoning cases attributable to new psychoactive substance use, the severity was fatal (n = 3), severe (n = 17), moderate (n = 67) and minor (n = 17). And 11 patients required intensive care unit admission. All three fatal cases were associated with para-methoxymethamphetamine use. Conclusion: A rising trend of new psychoactive substance use is observed locally, which is associated with considerable morbidity and mortality. Continued vigilance from frontline clinicians and medical professionals is imperative in the combat against new psychoactive substance use.


2018 ◽  
Vol 188 ◽  
pp. 126-134 ◽  
Author(s):  
Rachel Sutherland ◽  
Amy Peacock ◽  
Amanda Roxburgh ◽  
Monica J. Barratt ◽  
Lucinda Burns ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document